Evidence map›Paper›PMID 39663521›Full record

ArticleVirology journal2024

Correction: Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals.

Reem El-Shenawy, Rehab I Moustafa, Naiera M Helmy, Yasmine S El-Abd, Ashraf A Tabll, Yasser K Elesnawy, Heba Shawky

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Reem El-Shenawy *Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.ORCID http://orcid.org/0000-0001-7861-238X
Rehab I Moustafa *Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.ORCID http://orcid.org/0000-0002-8277-8304
Naiera M Helmy *Microbial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.ORCID http://orcid.org/0000-0003-3788-3372
Yasmine S El-AbdMicrobial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.ORCID http://orcid.org/0000-0002-8212-6146
Ashraf A TabllMicrobial Biotechnology Department, Biotechnology Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.ORCID http://orcid.org/0000-0001-7041-5445
Yasser K ElesnawyNational Committee for Control of Viral Hepatitis (NCCVH), Ministry of Health and Population, Cairo, Egypt.ORCID http://orcid.org/0000-0002-9863-5551
Heba ShawkyTherapeutic Chemistry Department, Pharmaceutical Industries and Drug Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt. hs.tohami@nrc.sci.eg.ORCID http://orcid.org/0000-0001-8403-1143

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39663521
PMCPMC11636224

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.